文献速递药物不良反应与药物警戒

欧盟风险最小化控制工具实施与使用:多利益相关方调查

Implementation and use of risk minimization control tools in the EU: A multistakeholder survey.
PubMed 文献 · Br J Clin Pharmacol · 2026-08-26

本研究在八个欧盟国家对八种药品的风险最小化控制工具(RMCT)实施情况开展横断面调查,共获得202份有效回复,代表286个利益相关方-产品组合。结果显示监管实施阶段难度评价异质,Fintepla®和Spravato®约75%受访者评为困难或非常困难,而Uptravi®约25%;整合入医疗体系阶段普遍较易。复杂性是监管实施主要障碍,行政负担是整合阶段主要障碍。

要点

  • 监管实施阶段难度因产品而异,Fintepla®和Spravato®约75%评为困难,Uptravi®约25%。
  • 整合入医疗体系阶段普遍较易,Fintepla®和Spravato®超90%评为容易或非常容易。
  • RMCT复杂性是监管实施主要障碍,行政负担是整合阶段主要障碍。

核心结论

  • RMCT实施总体可行,但监管实施阶段比整合入医疗体系阶段更具挑战性。

研究设计与样本

  • 横断面调查覆盖奥地利、希腊、拉脱维亚、荷兰、葡萄牙、斯洛文尼亚、西班牙和瑞典八国的国家主管机构、上市许可持有人、医师、药师等利益相关方。
  • 纳入Aspaveli®、Fintepla®、Revlimid®/仿制药、Soliris®/生物类似药、Spravato®、Strimvelis®、Uptravi®和Yescarta®八种药品。
  • 共获得202份有效回复,代表286个利益相关方-产品组合,采用描述性分析。

主要发现

  • 监管实施阶段体验异质:Fintepla®和Spravato®约75%受访者评为困难或非常困难,Uptravi®约25%。
  • 整合入医疗体系阶段普遍评为容易:Fintepla®和Spravato®超90%评为容易或非常容易,Revlimid®/仿制药约75%。
  • RMCT复杂性是监管实施主要障碍,既往经验和同行学习是促进因素。
  • 行政负担是整合阶段主要障碍,临床指南、培训、同行学习和既往经验促进整合。

关键数值与推荐

  • 监管实施困难或非常困难评价:Fintepla®和Spravato®约75%,Uptravi®约25%。
  • 整合入医疗体系容易或非常容易评价:Fintepla®和Spravato®超90%,Revlimid®/仿制药约75%。

临床怎么用

  • RMCT实施可考虑灵活设计、与现有系统对齐、可行性评估、利益相关方参与和清晰指导。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This study characterized stakeholders' experiences with national implementation of risk minimization control tools (RMCTs), such as healthcare professional qualification, healthcare facility accreditation and medical intervention prior to treatment initiation, for eight medicinal products across eight European Union countries. METHODS: We conducted a cross-sectional survey among national competent authorities, marketing authorization holders, physicians, pharmacists and other stakeholders involved in implementation or use of RMCTs in Austria, Greece, Latvia, the Netherlands, Portugal, Slovenia, Spain and Sweden. The following eight products were included: Aspaveli®, Fintepla®, Revlimid®/generics, Soliris®/biosimilars, Spravato®, Strimvelis®, Uptravi® and Yescarta®. Experiences were assessed across two implementation phases: regulatory implementation and integration into healthcare. Outcomes were perceived ease of implementation, barriers and enablers. Descriptive analyses were performed. RESULTS: We received 202 valid entries, representing 286 stakeholder-product combinations. Experiences with regulatory implementation were heterogeneous. Approximately 75% of respondents rated regulatory implementation as difficult or very difficult for Fintepla® and Spravato®, compared with about 25% for Uptravi®. The complexity of RMCTs was a key barrier, while prior experience and peer learning were enablers. Integration into healthcare was predominantly perceived as easy, with easy or very easy ratings ranging from over 90% for Fintepla® and Spravato® to about 75% for Revlimid®/generics. Administrative effort was the main barrier, whereas clinical guidelines, training, peer learning and prior experience facilitated integration. CONCLUSIONS: RMCT implementation was generally perceived as feasible, although regulatory implementation was more challenging than integration into healthcare. Successful implementation may benefit from flexible design, alignment with existing systems, feasibility assessment, stakeholder engagement and clear guidance.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Essink SCM, Joosse IR, Salcher-Konrad M, et al. Implementation and use of risk minimization control tools in the EU: A multistakeholder survey. Br J Clin Pharmacol. 2026. PMID: 42648741. doi:10.1002/bcp.70783

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。